skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 35  for All Library Resources

Results 1 2 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
Material Type:
Article
Add to My Research

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

Journal of clinical oncology, 2021-07, Vol.39 (20), p.JCO2003488-2303 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.20.03488 ;PMID: 33914595

Full text available

2
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
Material Type:
Article
Add to My Research

Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study

The lancet oncology, 2021-11, Vol.22 (11), p.1541-1559 [Peer Reviewed Journal]

2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;2021. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00402-2 ;PMID: 34600602

Full text available

3
Use of Prednisone With Abiraterone Acetate in Metastatic Castration‐Resistant Prostate Cancer
Material Type:
Article
Add to My Research

Use of Prednisone With Abiraterone Acetate in Metastatic Castration‐Resistant Prostate Cancer

The oncologist (Dayton, Ohio), 2014-12, Vol.19 (12), p.1231-1240 [Peer Reviewed Journal]

2014 AlphaMed Press ;AlphaMed Press. ;AlphaMed Press 2014 ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2014-0167 ;PMID: 25361624

Full text available

4
Population-based study of disease trajectory after radical treatment for high-risk prostate cancer
Material Type:
Article
Add to My Research

Population-based study of disease trajectory after radical treatment for high-risk prostate cancer

BJU international, 2024-04 [Peer Reviewed Journal]

2024 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International. ;ISSN: 1464-4096 ;ISSN: 1464-410X ;EISSN: 1464-410X ;DOI: 10.1111/bju.16362 ;PMID: 38621388

Full text available

5
A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients
Material Type:
Article
Add to My Research

A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients

World journal of urology, 2023-12, Vol.41 (12), p.3535-3542 [Peer Reviewed Journal]

The Author(s) 2023 ;EISSN: 1433-8726 ;DOI: 10.1007/s00345-023-04680-w

Digital Resources/Online E-Resources

6
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer : A subgroup analysis of the randomised clinical TITAN study
Material Type:
Article
Add to My Research

Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer : A subgroup analysis of the randomised clinical TITAN study

European journal of cancer (1990), 2023-11, Vol.193 [Peer Reviewed Journal]

ISSN: 0959-8049 ;EISSN: 1879-0852 ;DOI: 10.1016/j.ejca.2023.113290

Digital Resources/Online E-Resources

7
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN
Material Type:
Article
Add to My Research

Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

British journal of cancer, 2024-01, Vol.130 (1), p.73-81 [Peer Reviewed Journal]

2023. The Author(s). ;The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2023 ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/s41416-023-02492-8 ;PMID: 37951974

Full text available

8
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide
Material Type:
Article
Add to My Research

Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide

Prostate cancer and prostatic diseases, 2023-03, Vol.26 (1), p.156-161 [Peer Reviewed Journal]

2022. The Author(s), under exclusive licence to Springer Nature Limited. ;The Author(s), under exclusive licence to Springer Nature Limited 2022. corrected publication 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. ;ISSN: 1365-7852 ;EISSN: 1476-5608 ;DOI: 10.1038/s41391-022-00592-9 ;PMID: 36209239

Full text available

9
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study
Material Type:
Article
Add to My Research

Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study

Future oncology (London, England), 2024-03, Vol.20 (10), p.563-578 [Peer Reviewed Journal]

2023 The Authors ;ISSN: 1479-6694 ;EISSN: 1744-8301 ;DOI: 10.2217/fon-2023-0649

Digital Resources/Online E-Resources

10
Increased levels and activity of E2F1 transcription factor in myelodysplastic bone marrow
Material Type:
Article
Add to My Research

Increased levels and activity of E2F1 transcription factor in myelodysplastic bone marrow

International journal of hematology, 2004-08, Vol.80 (2), p.146-154 [Peer Reviewed Journal]

2004 INIST-CNRS ;The Japanese Society of Hematology 2004 ;ISSN: 0925-5710 ;EISSN: 1865-3774 ;DOI: 10.1532/IJH97.NA0303 ;PMID: 15481443

Full text available

11
Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes
Material Type:
Article
Add to My Research

Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes

Future oncology (London, England), 2007-08, Vol.3 (4), p.397-403 [Peer Reviewed Journal]

2007 © Future Medicine Ltd ;ISSN: 1479-6694 ;EISSN: 1744-8301 ;DOI: 10.2217/14796694.3.4.397 ;PMID: 17661714

Full text available

12
Clinical implications of advanced molecular cytogenetics in cancer
Material Type:
Article
Add to My Research

Clinical implications of advanced molecular cytogenetics in cancer

Expert review of molecular diagnostics, 2004-01, Vol.4 (1), p.71-81 [Peer Reviewed Journal]

2004 Future Drugs Ltd. All rights reserved. 2004 ;Copyright Future Drugs Ltd. ;ISSN: 1473-7159 ;EISSN: 1744-8352 ;DOI: 10.1586/14737159.4.1.71 ;PMID: 14711351

Full text available

13
Correlation of tumor necrosis factor α (TNFα) with high Caspase 3-like activity in myelodysplastic syndromes
Material Type:
Article
Add to My Research

Correlation of tumor necrosis factor α (TNFα) with high Caspase 3-like activity in myelodysplastic syndromes

Cancer letters, 1999-06, Vol.140 (1), p.201-207 [Peer Reviewed Journal]

1999 ;1999 INIST-CNRS ;ISSN: 0304-3835 ;EISSN: 1872-7980 ;DOI: 10.1016/S0304-3835(99)00072-5 ;PMID: 10403560 ;CODEN: CALEDQ

Full text available

14
PATIENT RETENTION AND PHYSICIAN ENGAGEMENT STRATEGIES DURING THE COVID-19 PANDEMIC IN THE PHASE 3 ATLAS STUDY OF APALUTAMIDE ADDED TO ANDROGEN DEPRIVATION THERAPY IN HIGHRISK LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER
Material Type:
Article
Add to My Research

PATIENT RETENTION AND PHYSICIAN ENGAGEMENT STRATEGIES DURING THE COVID-19 PANDEMIC IN THE PHASE 3 ATLAS STUDY OF APALUTAMIDE ADDED TO ANDROGEN DEPRIVATION THERAPY IN HIGHRISK LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER

Oncology nursing forum, 2023-03, Vol.50 (2), p.A13-A14 [Peer Reviewed Journal]

Copyright Oncology Nursing Society Mar 2023 ;ISSN: 0190-535X ;EISSN: 1538-0688

Full text available

15
DEVELOPMENT OF A RETROSPECTIVE CLINICIAN-ADMINISTERED SURVEY STUDY (RETROCLASS) ASSESSING EFFICACY AND TREATMENT BURDEN IN PROSTATE CANCER PATIENTS
Material Type:
Article
Add to My Research

DEVELOPMENT OF A RETROSPECTIVE CLINICIAN-ADMINISTERED SURVEY STUDY (RETROCLASS) ASSESSING EFFICACY AND TREATMENT BURDEN IN PROSTATE CANCER PATIENTS

Oncology nursing forum, 2022-03, Vol.49 (2), p.24-25 [Peer Reviewed Journal]

Copyright Oncology Nursing Society Mar 2022 ;ISSN: 0190-535X ;EISSN: 1538-0688

Full text available

16
Apalutamide plus abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, phase 3 study
Material Type:
Article
Add to My Research

Apalutamide plus abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, phase 3 study

The lancet oncology, 2021-09, Vol.22 (11), p.1541-1559 [Peer Reviewed Journal]

ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00402-2 ;PMID: 34600602

Full text available

17
Caspases and apoptosis in myelodysplastic syndromes
Material Type:
Article
Add to My Research

Caspases and apoptosis in myelodysplastic syndromes

Experimental hematology, 2000-12, Vol.28 (12), p.1310-1311 [Peer Reviewed Journal]

2000 International Society for Experimental Hematology. ;ISSN: 0301-472X ;EISSN: 1873-2399 ;DOI: 10.1016/S0301-472X(00)00607-X ;PMID: 11188920

Full text available

18
In Reply
Material Type:
Article
Add to My Research

In Reply

The oncologist (Dayton, Ohio), 2015-05, Vol.20 (5), p.e14-e14 [Peer Reviewed Journal]

AlphaMed Press 2015 ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2015-0010 ;PMID: 25888269

Full text available

19
In Reply
Material Type:
Article
Add to My Research

In Reply

The oncologist (Dayton, Ohio), 2015-05, Vol.20 (5), p.e14-e14 [Peer Reviewed Journal]

2015 AlphaMed Press ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2015-0010

Full text available

20
In Reply
Material Type:
Article
Add to My Research

In Reply

The oncologist (Dayton, Ohio), 2015-05, Vol.20 (5), p.e14-e14 [Peer Reviewed Journal]

ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2015-0010

Full text available

Results 1 - 20 of 35  for All Library Resources

Results 1 2 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (33)

Refine My Results

Creation Date 

From To
  1. Before 1996  (3)
  2. 1996 To 1999  (5)
  3. 2000 To 2006  (7)
  4. 2007 To 2021  (12)
  5. After 2021  (9)
  6. More options open sub menu

Resource Type 

  1. Articles  (34)
  2. Patents  (1)
  3. More options open sub menu

Searching Remote Databases, Please Wait